Background: A negative-controlled, randomized, blinded laboratory study in 31 cats was carried out to evaluate the preventive efficacy of a topical parasiticide (Bravecto Plus spot-on solution for cats, MSD) against infections with the cat lungworm Aelurostrongylus abstrusus. The study was approved by the ethics commission of the Institutional Animal Care and Use Committee (IACUC). Material and Methods: The recommended minimum dose of 40 mg fluralaner and 2.0 mg moxidectin per kilogram bodyweight was administered either 12 (group[G] 1), 8 (G2) or 4 (G3) weeks before the infection with 300 third stage larvae of A. abstrusus. Starting on day 30 post infection (d.p.i.), the fecal larval shedding was monitored. On 47-51 d.p.i., the animals were humanly euthanized, the lungs were evaluated macroscopically for pathological findings and (pre-)adult A. abstrusus were counted. Results: All cats in the control group started continuous larval shedding between 32-40 d.p.i., whereas only in one animal of G1 larvae were present in the feces on several consecutive days. Another seven animals were copromicroscopically positive on one single day. Geometric mean (GM) of the maximum number of larvae shed on one day was 7574.29 in the control group compared to 1.10 (G1), 1.19 (G2) and 0.53 (G3). Thus, the administration of Bravecto Plus spot-on solution for cats reduced larval shedding by 99.98% (G2) to 99.99% (G1 and 3). All lungs in the control group showed severe to extremely severe pathological findings, whereas in 95.65% of the treated cats none or mild pathological findings were detected. The GM of isolated (pre-)adult A. abstrusus from the lungs was 26.57 in the control group compared to 0.09 (G1) and 0.00 (G2 and 3). Thus, the reduction of worm burden was 99.66% (G1) and 100% (G2 and 3). Conclusion: A single administration of Bravecto Plus spot-on solution for cats was effective in prevention of aelurostrongylosis for at least 12 weeks.
Preventive efficacy of Bravecto Plus spot-on for cats (280mg/ml fluralaner and 14mg/ml moxidectin) against aelurostrongylosis in experimentally infected cats
Traversa D;Di Cesare A;Morelli S;
2020-01-01
Abstract
Background: A negative-controlled, randomized, blinded laboratory study in 31 cats was carried out to evaluate the preventive efficacy of a topical parasiticide (Bravecto Plus spot-on solution for cats, MSD) against infections with the cat lungworm Aelurostrongylus abstrusus. The study was approved by the ethics commission of the Institutional Animal Care and Use Committee (IACUC). Material and Methods: The recommended minimum dose of 40 mg fluralaner and 2.0 mg moxidectin per kilogram bodyweight was administered either 12 (group[G] 1), 8 (G2) or 4 (G3) weeks before the infection with 300 third stage larvae of A. abstrusus. Starting on day 30 post infection (d.p.i.), the fecal larval shedding was monitored. On 47-51 d.p.i., the animals were humanly euthanized, the lungs were evaluated macroscopically for pathological findings and (pre-)adult A. abstrusus were counted. Results: All cats in the control group started continuous larval shedding between 32-40 d.p.i., whereas only in one animal of G1 larvae were present in the feces on several consecutive days. Another seven animals were copromicroscopically positive on one single day. Geometric mean (GM) of the maximum number of larvae shed on one day was 7574.29 in the control group compared to 1.10 (G1), 1.19 (G2) and 0.53 (G3). Thus, the administration of Bravecto Plus spot-on solution for cats reduced larval shedding by 99.98% (G2) to 99.99% (G1 and 3). All lungs in the control group showed severe to extremely severe pathological findings, whereas in 95.65% of the treated cats none or mild pathological findings were detected. The GM of isolated (pre-)adult A. abstrusus from the lungs was 26.57 in the control group compared to 0.09 (G1) and 0.00 (G2 and 3). Thus, the reduction of worm burden was 99.66% (G1) and 100% (G2 and 3). Conclusion: A single administration of Bravecto Plus spot-on solution for cats was effective in prevention of aelurostrongylosis for at least 12 weeks.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
